HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC noted, "We are not ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

Zeit Aktuelle Nachrichten 10:30 HSBC cuts Eli Lilly stock rating to Reduce, target to $700 09:43 UNGLAUBLICHE Sondermeldung bei Eli Lilly Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.